TBC
NVO

Ted Buchan & Co’s Novo Nordisk NVO Stock Holding History

Ted Buchan & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Sell
61,298
-9,535
-13% -$410K 0.96% 26
2026
Q1 		$2.6M Buy
70,833
+32,294
+84% +$1.53M 0.95% 27
2025
Q4 		$1.96M Buy
38,539
+11,036
+40% +$564K 0.72% 32
2025
Q3 		$1.53M Buy
+27,503
New +$1.61M 0.6% 38

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ted Buchan & Co's NVO Position: Q2 2026 in Review

Ted Buchan & Co reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $410K and leaving 61,298 shares worth $2.94M. The position accounts for 0.96% of the portfolio, ranked #26.

Ted Buchan & Co first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ted Buchan & Co held 61,298 shares of Novo Nordisk worth $2.94M as of Q2 2026.
  • Ted Buchan & Co sold 9,535 Novo Nordisk shares in Q2 2026, an estimated $410K.
  • Novo Nordisk made up 0.96% of Ted Buchan & Co's portfolio in Q2 2026, its #26 holding.
  • Ted Buchan & Co first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ted Buchan & Co's 13F filing for Q2 2026, filed 23 Jul 2026.